Rocket Pharma Gets FDA Alignment On This Key Trial -- A Look At Some Key Highlights
Rocket Pharmaceuticals Inc. (RCKT) shares rose more than 5% in Tuesday’s opening trade before paring all the gains after the company said it reached alignment with the U.S. Food and Drug Administration on key elements needed to complete its pivotal Phase 2 trial of RP-A501 in Danon disease.RP-A501…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.